NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -4.8% ·
aandelenstroom +7.5% ·
netto nieuwe posities -5.0%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 642.22K | $90.01M | n/a | −3 |
| Q2 2026 | 152 | 0 | 75.82M | $12.77B | +5 | −6 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 12.95M | n/a | $1.63B | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (passief) | 9.81M | n/a | $1.23B | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | Dodge & Cox ✦ | 5.57M | +0.6% | $699.69M | 0.4% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passief) | 4.47M | -8.1% | $561.62M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 3.09M | +100.5% | $387.94M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 2.37M | -5.5% | $297.43M | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 2.05M | +130.5% | $257.55M | 0.2% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 2.03M | -3.3% | $255.01M | 0.0% | ▼ Trim | 5 | SEC ↗ ×6 |
| 9 | Geode Capital Management ✦ (passief) | 1.96M | -0.5% | $245.57M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 10 | AQR Capital Management ✦ | 1.51M | +40.5% | $189.79M | 0.2% | ▲ Add | 5 | SEC ↗ ×8 |
| 11 | Millennium Management ✦ | 1.19M | +107.1% | $150.10M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 12 | Norges Bank ✦ (passief) | 972.86K | -2.7% | $122.28M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 524.04K | +37.0% | $65.87M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 341.58K | Nieuw | $42.93M | 0.1% | New | 1 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 254.84K | n/a | $32.03M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 16 | Arrowstreet Capital ✦ | 125.16K | +87.9% | $15.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 91.13K | +193.8% | $11.45M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 87.54K | -8.1% | $11.00M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Marshall Wace ✦ | 41.65K | Nieuw | $5.23M | 0.0% | New | 1 | SEC ↗ ×3 |
| 20 | Bridgewater Associates ✦ | 8.94K | -89.8% | $1.12M | 0.0% | ▼ Trim | 5 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Adage Capital Partners | $42.93M | 0.1% |
| Marshall Wace | $5.23M | 0.0% |
Verlaten
| Soros Fund Management | $26.52M | was 0.7% |
| D. E. Shaw & Co. | $1.61M | was 0.0% |
| Two Sigma Investments | $1.13M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 690 houders, 94.09M aandelen, $12.08B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 826 aand · $130,051
Officer · 2.31K aand · $363,285
Officer · 2.15K aand · $333,030
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie